AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 41 min read$RMD

FARRELL PETER C sold $228K of RMD

FARRELL PETER C sold 970 shares of RESMED INC (RMD) at $234.73 ($0.23M total) on 2026-09-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · FARRELL PETER C
Published Sep 4, 2026, 10:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 10:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RMD
Neutral
high confidence
Mentioned
$RMD
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RMDNeutralLow
01

Why it matters

Provides a primary source of insider sale data; limited trading relevance.

02

Market read

Small insider sale with minimal market impact.

03

What to watch

Potential upcoming earnings or product news may dominate price action.

Relevance 3/10Novelty 4/10Timing: filing date 2026-09-04

Background

SEC Form 4 filing discloses insider transactions.

Company-level read

Ticker impact

$RMDNeutralHigh confidence
Context

Director Peter Farrell sold 970 shares of ResMed for $227,688 on 2026-09-02 via a 10b5‑1 plan.

Expected impact

Minimal impact; price likely unchanged.

Evidence & confidence

The sale size is small relative to total float and insider holdings remain substantial.

Market effects

Sector

None significant for the medical device sector.

Regional

No regional effect.

Global

Limited to ResMed investors.

Counterpoint

What could challenge this read

Insider sale could signal concerns, but size is trivial.

Key entities

  • Company
    ResMed Inc.

    Medical device manufacturer.

  • Individual
    Peter Farrell

    Director of ResMed.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RMD insider trading history →

Related articles

SEP 28
$RMDMed

Health Check: No 'Wharfie Time' curse as healthcare stocks kick away from the pack

ASX healthcare stocks, led by CSL (ASX:CSL) and ResMed (ASX:RMD), gained institutional investor interest, with Morgan Stanley noting increased overweight positions. RBC Capital upgraded several healthcare stocks, citing better-than-expected earnings. Healius (ASX:HLS) plans to sell Agilex for $160M to Novotech, addressing balance sheet challenges. Paradigm Biopharmaceuticals (ASX:PAR) delayed its trading resumption to address financial matters.

stockhead.com.au5 min
SEP 16
$RMDMed

CSL, Resmed, and more. See which ASX health stocks RBC Capital Markets has upgraded

RBC Capital Markets upgraded five ASX-listed healthcare stocks to outperform, citing positive earnings growth and attractive valuations. CSL (ASX: CSL) was highlighted for market share gains, with a $213 price target. ResMed (ASX: RMD) was noted for capital management, with a $262 target. Ramsay Healthcare (ASX: RHC) was praised for cost control, with a $68 target. Fisher & Paykel (ASX: FPH) showed strong growth, with a $52 target. Nanosonics (ASX: NAN) had mixed results but a $3.75 target.

fool.com.au2 min
SEP 16
$RMDMed

ResMed Shares Jump Following RBC Capital Upgrade to Outperform

ResMed (RMD) stock rose 3% after RBC Capital upgraded it to Outperform, raising the price target to $262. Analyst Craig Wong-Pan cited strong growth in sleep devices, both in the Americas and internationally, and projected high single-digit EPS growth over three years. The FDA's recall of a competing device also boosted sentiment.

tikr.com2 min
SEP 15
$RMDHighAI 8/10

Why is ResMed stock rallying today?

ResMed (RMD) stock rose 2.9% after providing fiscal 2027 guidance, projecting 5%-7% revenue growth and 12%-14% EPS growth. RBC upgraded RMD to Outperform, raising its price target to $262. Despite broader market declines, RMD's positive outlook resonated with investors, addressing concerns about GLP-1 headwinds and competition.

investing.com2 min